Paramount Subscribers; New Drugs for Macular Degeneration; Sportradar Eyes U.S.

Paramount Subscribers; New Drugs For Macular Degeneration; Sportradar Eyes U.s.

In our weekly round-up of the top charts and market-moving analyst insights, Paramount’s streaming subscribers are projected to grow, new drugs for age-related macular degeneration are projected to challenge market leaders, and Sportradar’s U.S. business is expected to drive growth.

Paramount Forecasted to Have Over 100M Streaming Subscribers by 2024

Analysts believe Paramount (PARA_US) will have over 100M global streaming subscribers by 2024, according to Visible Alpha consensus. The company recently reported an additional 10.8M subscribers in Q4 2022 driven by popular content such as Yellowstone, Top Gun: Maverick, and Tulsa King.

Paramount Forecasted to Have Over M Streaming Subscribers by

New Wet AMD Inhibitors May Erode Sales of Market Leading Drugs, Say Analysts

Analysts believe that if novel anti-angiogenesis drugs are approved, market-leading Wet Age-Related Macular Degeneration (Wet AMD) drugs Eylea (Regeneron [REGN]) and Lucentis ([Novartis-NOVN_CH], Roche [ROG_CH]) may face eroding sales in the near future. Recently, Ocular Therapeutics (OCUL) reported Phase 1 data, while Opthea (OPT_AU) reported Phase 2b data for complementary drugs.

New Wet AMD Inhibitors May Erode Sales of Market Leading Drugs Say Analysts

Sportradar’s U.S. Business Expected To Drive Growth Going Forward, Say Analysts

Analysts believe Sportradar’s (SRAD_US) U.S. business will grow by over 40% YoY next year as the sports data analytics company benefits from the legalization of online sports betting. The Switzerland-based company has become a leading provider of sports data for oddsmakers.



Tags: , ,